Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Alkaptonuria

In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993.
[updated ].
Affiliations
Free Books & Documents
Review

Alkaptonuria

Wendy J Introne et al.
Free Books & Documents

Excerpt

Clinical characteristics: Alkaptonuria is caused by deficiency of homogentisate 1,2-dioxygenase, an enzyme that converts homogentisic acid (HGA) to maleylacetoacetic acid in the tyrosine degradation pathway. The three major features of alkaptonuria are dark urine or urine that turns dark on standing, ochronosis (bluish-black pigmentation in connective tissue), and arthritis of the spine and larger joints. Ochronosis generally occurs after age 30 years; arthritis often begins in the third decade. Other manifestations can include pigment in the sclera, ear cartilage, and skin of the hands; aortic or mitral valve calcification or regurgitation and occasionally aortic dilatation; renal stones; prostate stones; and hypothyroidism.

Diagnosis/testing: The biochemical diagnosis of alkaptonuria in a proband is based on the detection of a significant amount of HGA in the urine (usually 1 to 8 grams per day).

The molecular diagnosis (needed to provide genetic counseling to family members) is based on identification of biallelic pathogenic variants in HGD.

Management: Treatment of manifestations: Symptomatic management of joint pain is tailored to the individual; physical and occupational therapy help promote optimal muscle strength and flexibility; knee, hip, and shoulder replacements are options when needed; surgical intervention for prostate stones and renal stones as needed; aortic stenosis may necessitate valve replacement; thyroid hormone replacement.

Treatment with nitisinone, which has been shown to slow the progression of symptoms, is approved for use in treatment of alkaptonuria in Europe but not the United States.

Surveillance: In individuals older than age 40 years, echocardiography to detect aortic dilatation, aortic or mitral valve calcification, and stenosis. In individuals with suggestive symptoms, consider CT imaging to detect coronary artery calcification. Assess thyroid function at the time of initial diagnosis, and monitor every 1-2 years thereafter.

Agents/circumstances to avoid: Physical stress to the spine and large joints (including heavy manual labor or high-impact sports) to try to reduce progression of severe arthritis.

Evaluation of relatives at risk: It is appropriate to evaluate apparently asymptomatic older and younger sibs of an affected individual in order to identify as early as possible those who would benefit from preventive measures to help preserve overall joint mobility and function.

Genetic counseling: Alkaptonuria is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for an HGD pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. When both HGD pathogenic variants in the family are known, carrier testing for at-risk relatives and prenatal/preimplantation genetic testing are possible.

PubMed Disclaimer

Similar articles

  • Mucopolysaccharidosis Type IVA.
    Regier DS, Oetgen M, Tanpaiboon P. Regier DS, et al. 2013 Jul 11 [updated 2021 Jun 17]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2013 Jul 11 [updated 2021 Jun 17]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 23844448 Free Books & Documents. Review.
  • Aromatic L-Amino Acid Decarboxylase Deficiency.
    Blau N, Pearson TS, Kurian MA, Elsea SH. Blau N, et al. 2023 Oct 12 [updated 2025 Jan 23]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2023 Oct 12 [updated 2025 Jan 23]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 37824694 Free Books & Documents. Review.
  • Gene expression & biochemical analysis in alkaptonuria caused by a founder pathogenic variant across different age groups from India.
    Abraham SSC, Barney A, Mohan S, Joy P, Ganesan P, Das S, Cherupanakkal C, Jose A, A R, Zatkova A, Danda S. Abraham SSC, et al. Indian J Med Res. 2024 Nov;160(5):448-456. doi: 10.25259/ijmr_1900_23. Indian J Med Res. 2024. PMID: 39737503 Free PMC article.
  • Alpha-Mannosidosis.
    Ficicioglu C, Stepien KM. Ficicioglu C, et al. 2001 Oct 11 [updated 2024 Jun 13]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2001 Oct 11 [updated 2024 Jun 13]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301570 Free Books & Documents. Review.
  • Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review.
    Fisher AA, Davis MW. Fisher AA, et al. Clin Med Res. 2004 Nov;2(4):209-15. doi: 10.3121/cmr.2.4.209. Clin Med Res. 2004. PMID: 15931360 Free PMC article. Review.

References

    1. Ascher DB, Spiga O, Sekelska M, Pires DEV, Bernini A, Tiezzi M, Kralovicova J, Borovska I, Soltysova A, Olsson B, Galderisi S, Cicaloni V, Ranganath L, Santucci A, Zatkova A. Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype-phenotype correlations in the largest cohort of patients with AKU. Eur J Hum Genet. 2019;27:888–902. - PMC - PubMed
    1. Avadhanula S, Introne WJ, Auh S, Soldin SJ, Stolze B, Regier D, Ciccone C, Hannah-Shmouni F, Filie AC, Burman KD, Klubo-Gwiezdzinska J. Assessment of thyroid function in patients with alkaptonuria. JAMA Netw Open. 2020;3:e201357. - PMC - PubMed
    1. Beltrán-Valero de Bernabé D, Granadino B, Chiarelli I, Porfirio B, Mayatepek E, Aquaron R, Moore MM, Festen JJ, Sanmartí R, Peñalva MA, de Córdoba SR. Mutation and polymorphism analysis of the human homogentisate 1, 2-dioxygenase gene in alkaptonuria patients. Am J Hum Genet. 1998;62:776–84. - PMC - PubMed
    1. Beltrán-Valero de Bernabé D, Peterson P, Luopajarvi K, Matintalo P, Alho A, Konttinen Y, Krohn K, Rodriguez de Cordoba S, Ranki A. Mutational analysis of the HGO gene in Finnish alkaptonuria patients. J Med Genet. 1999;36:922–3. - PMC - PubMed
    1. Chévez Barrios P, Font RL. Pigmented conjunctival lesions as initial manifestation of ochronosis. Arch Ophthalmol. 2004;122:1060–3. - PubMed

LinkOut - more resources